Skip to content
Home » Medicine » COVID-19 » Page 3

COVID-19

myocarditis COVID-19 vaccines

Myocarditis and COVID vaccines – what are the facts?

While myocarditis, a rare inflammation of the heart often caused by viruses, has been linked to COVID-19 vaccines, the risk is negligible. Most cases occur in young men after multiple doses and resolve within 90 days without serious harm. The risk of getting myocarditis from a COVID-19 vaccine is significantly lower than the risk of myocarditis from the disease itself. Despite fears, there are no recorded deaths due to myocarditis post-vaccination.

rsv COVID flu tripledemic

Flu, COVID, RSV on the rise — beware the tripledemic

The USA, including California, faces a ‘tripledemic’ of seasonal flu, new COVID-19 variants, and respiratory syncytial virus (RSV). All three respiratory viruses, particularly harmful to seniors and children, can be prevented through vaccination. Despite this, many places are reporting low vaccination rates, especially among older people. The content highlights RSV’s severity and contagion, recent research into the virus, and the situation with the three diseases in California and other states.

COVID vaccine development process – how it compares to “normal”

The development process for COVID-19 vaccines was accelerated yet robust and thorough, maintaining rigorous safety and effectiveness standards. Efforts to speed up the process included enrolling over 100,000 patients worldwide, fast-tracking data analysis and regulatory reviews, and preparing manufacturing facilities. Despite the rapid pace, multiple independent agencies and expert groups ensured vaccine safety and effectiveness, making it nearly impossible for a harmful vaccine to reach the market. This process, vital in saving lives amidst the pandemic, still follow established protocols used in pre-pandemic vaccine development.

JN.1

New JN.1 COVID variant may become a concern

The COVID-19 variant JN.1, a descendent lineage of Omicron subvariant BA.2.86, is causing public health concerns although there is no current evidence of increased risk. The CDC is closely monitoring this variant, comprising 15-29% of US COVID-19 cases. Preliminary research indicates existing vaccines may protect against JN.1. However, the effect on immunity from natural infection is unknown.

BA.2.86 variant

New information on the BA.2.86 COVID variant

The BA.2.86 variant of the SARS-CoV-2 virus, also called the Pirola variant, is back on the CDC’s radar despite not causing significant infection increases previously. It may evade vaccines or natural immunity and is currently accounting for 9% of cases but isn’t driving infection or hospitalization increases. The public health risk is considered low compared to other variants. Vaccinated individuals have reduced risk of hospitalization, and there is no evidence the strain can evade vaccine or natural immunity entirely. Updates will continue as the situation develops.

We Want Them Infected

Review of the book “We Want Them Infected” by Jonathan Howard

“We Want Them Infected,” by Jonathan Howard, critically analyzes the US response to the COVID-19 pandemic. The book scrutinizes how doctors spread misinformation, the harm of mass infection policies, and the controversial concept of herd immunity. It is praised for its rigorous research, insights into future virus management, and comprehensive critique of pandemic handling.